Elligo Health Research, a healthcare-enabling research organization, announced its partnership with Austin Cancer Center (ACC), an independent oncology group in central Texas. The partnership expands Elligo’s Research Ready network to include its first oncology practice, broadening Elligo’s therapeutic specialization and allowing ACC’s oncologists to offer research as a care option. ACC is currently enrolling patients for studies in breast cancer.
“Partnering with Elligo allows us to bring cutting-edge capabilities to our patients,” said Blayne Rush, MBA, ACC’s CEO. “We’re excited they can remain under our care while benefiting from the innovative treatments available through participation in clinical studies.”
“Bringing the Research Ready network to cancer patients in this area is a milestone achievement in our promise to preserve the trusted patient and physician relationship and unite the best clinical experts with the best research infrastructure,” said John Potthoff, PhD, Elligo’s CEO.
Learn more at elligodirect.com
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.